» Articles » PMID: 17645546

Expression, Post-translational Modification and Biochemical Characterization of Proteins Encoded by Subgenomic MRNA8 of the Severe Acute Respiratory Syndrome Coronavirus

Overview
Journal FEBS J
Specialty Biochemistry
Date 2007 Jul 25
PMID 17645546
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The most striking difference between the subgenomic mRNA8 of severe acute respiratory syndrome coronavirus isolated from human and some animal species is the deletion of 29 nucleotides, resulting in splitting of a single ORF (ORF8) into two ORFs (ORF8a and ORF8b). ORF8a and ORF8b are predicted to encode two small proteins, 8a and 8b, and ORF8 a single protein, 8ab (a fusion form of 8a and 8b). To understand the functions of these proteins, we cloned cDNA fragments covering these ORFs into expression plasmids, and expressed the constructs in both in vitro and in vivo systems. Expression of a construct containing ORF8a and ORF8b generated only a single protein, 8a; no 8b protein expression was obtained. Expression of a construct containing ORF8 generated the 8ab fusion protein. Site-directed mutagenesis and enzymatic treatment revealed that protein 8ab is modified by N-linked glycosylation on the N81 residue and by ubiquitination. In the absence of the 8a region, protein 8b undergoes rapid degradation by proteasomes, and addition of proteasome inhibitors inhibits the degradation of protein 8b as well as the protein 8b-induced rapid degradation of the severe acute respiratory syndrome coronavirus E protein. Glycosylation could also stabilize protein 8ab. More interestingly, the two proteins could bind to monoubiquitin and polyubiquitin, suggesting the potential involvement of these proteins in the pathogenesis of severe acute respiratory syndrome coronavirus.

Citing Articles

UBR5 Acts as an Antiviral Host Factor against MERS-CoV via Promoting Ubiquitination and Degradation of ORF4b.

Zhou Y, Zheng R, Liu D, Liu S, Disoma C, Li S J Virol. 2022; 96(17):e0074122.

PMID: 35980206 PMC: 9472757. DOI: 10.1128/jvi.00741-22.


Host-Genome Similarity Characterizes the Adaption of SARS-CoV-2 to Humans.

Sun W Biomolecules. 2022; 12(7).

PMID: 35883528 PMC: 9312508. DOI: 10.3390/biom12070972.


Exploring Virome Diversity in Public Data in South America as an Approach for Detecting Viral Sources From Potentially Emerging Viruses.

Mazur F, Morinisi L, Martins J, Guerra P, Freire C Front Genet. 2022; 12:722857.

PMID: 35126446 PMC: 8814814. DOI: 10.3389/fgene.2021.722857.


Lost in deletion: The enigmatic ORF8 protein of SARS-CoV-2.

Zinzula L Biochem Biophys Res Commun. 2021; 538:116-124.

PMID: 33685621 PMC: 7577707. DOI: 10.1016/j.bbrc.2020.10.045.


Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country.

Requena D, Medico A, Chacon R, Ramirez M, Marin-Sanchez O Front Immunol. 2020; 11:2008.

PMID: 33013857 PMC: 7494848. DOI: 10.3389/fimmu.2020.02008.


References
1.
Hofmann K, Falquet L . A ubiquitin-interacting motif conserved in components of the proteasomal and lysosomal protein degradation systems. Trends Biochem Sci. 2001; 26(6):347-50. DOI: 10.1016/s0968-0004(01)01835-7. View

2.
Hicke L, Schubert H, Hill C . Ubiquitin-binding domains. Nat Rev Mol Cell Biol. 2005; 6(8):610-21. DOI: 10.1038/nrm1701. View

3.
Law P, Liu Y, Geng H, Kwan K, Waye M, Ho Y . Expression and functional characterization of the putative protein 8b of the severe acute respiratory syndrome-associated coronavirus. FEBS Lett. 2006; 580(15):3643-8. PMC: 7094570. DOI: 10.1016/j.febslet.2006.05.051. View

4.
Shiba Y, Katoh Y, Shiba T, Yoshino K, Takatsu H, Kobayashi H . GAT (GGA and Tom1) domain responsible for ubiquitin binding and ubiquitination. J Biol Chem. 2003; 279(8):7105-11. DOI: 10.1074/jbc.M311702200. View

5.
Zeng R, Yang R, Shi M, Jiang M, Xie Y, Ruan H . Characterization of the 3a protein of SARS-associated coronavirus in infected vero E6 cells and SARS patients. J Mol Biol. 2004; 341(1):271-9. PMC: 7127270. DOI: 10.1016/j.jmb.2004.06.016. View